SYK

Prezzo Stryker Corp

Closed
SYK
$287,80
-$6,70(-2,27%)

*Data last updated: 2026-05-10 06:47 (UTC+8)

As of 2026-05-10 06:47, Stryker Corp (SYK) is priced at $287,80, with a total market cap of $109,33B, a P/E ratio of 41,38, and a dividend yield of 1,20%. Today, the stock price fluctuated between $284,95 and $297,99. The current price is 1,00% above the day's low and 3,41% below the day's high, with a trading volume of 1,45M. Over the past 52 weeks, SYK has traded between $284,95 to $345,88, and the current price is -16,79% away from the 52-week high.

SYK Key Stats

Yesterday's Close$294,23
Market Cap$109,33B
Volume1,45M
P/E Ratio41,38
Dividend Yield (TTM)1,20%
Dividend Amount$0,88
Diluted EPS (TTM)8,71
Net Income (FY)$3,24B
Revenue (FY)$25,11B
Earnings Date2026-07-30
EPS Estimate3,47
Revenue Estimate$6,58B
Shares Outstanding371,58M
Beta (1Y)0.81
Ex-Dividend Date2026-03-31
Dividend Payment Date2026-04-30

About SYK

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
SectorHealthcare
IndustryMedical - Devices
CEOKevin A. Lobo
HeadquartersPortage,MI,US
Official Websitehttps://www.stryker.com
Employees (FY)56,00K
Average Revenue (1Y)$448,50K
Net Income per Employee$57,96K

Stryker Corp (SYK) FAQ

What's the stock price of Stryker Corp (SYK) today?

x
Stryker Corp (SYK) is currently trading at $287,80, with a 24h change of -2,27%. The 52-week trading range is $284,95–$345,88.

What are the 52-week high and low prices for Stryker Corp (SYK)?

x

What is the price-to-earnings (P/E) ratio of Stryker Corp (SYK)? What does it indicate?

x

What is the market cap of Stryker Corp (SYK)?

x

What is the most recent quarterly earnings per share (EPS) for Stryker Corp (SYK)?

x

Should you buy or sell Stryker Corp (SYK) now?

x

What factors can affect the stock price of Stryker Corp (SYK)?

x

How to buy Stryker Corp (SYK) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Stryker Corp (SYK)

CommunityLurker

CommunityLurker

05-08 13:39
Just caught wind of Stryker dropping their T2 Alpha Humerus Nailing System and honestly, this is worth paying attention to if you're tracking the orthopedic space. They're basically expanding their T2 Alpha lineup with a new solution specifically designed for complex humeral fracture management, which is a pretty specific play in the trauma devices market. What caught my eye is how they're leveraging their SOMA technology (Stryker Orthopaedic Modeling and Analytics) to engineer this thing. The system handles some gnarly cases including non-unions, malunions, malalignments and pathological fractures. The anatomy-informed nail design is supposed to improve alignment with patient anatomy and enhance fixation stability. They're also offering up to 6mm of active intraoperative compression, which beats conventional techniques, plus multiplanar screw fixation with advanced locking configs to engage denser bone structures. From a procedural standpoint, the guided targeting instrumentation reduces intraoperative radiation exposure and supports reproducibility in the OR. Integration with their existing nailing platform means surgeons get consistency across different cases, streamlined training, and better operational efficiency at the hospital level. That's the kind of cross-portfolio synergy that drives adoption. Stock-wise, SYK gained 0.7% on the news, though the broader picture shows some volatility. Over the past six months, shares are down 3.4% versus an 11.6% industry decline, so relatively holding up. The company sits at a $138.08 billion market cap, which gives them the scale to push innovations like this. The market tailwinds are real too. According to recent data, the trauma and extremities devices market is valued at $16.55 billion in 2026 and expected to grow at a 5.2% CAGR through 2034. Increasing orthopedic injuries, aging demographics, and ongoing development in less invasive techniques like intramedullary nails and locking plate systems are all fueling expansion. The humerus fracture space is a subset of this, but it's a meaningful one. Interestingly, Stryker also just announced limited market release of their Mako RPS for Total Knee, which shows they're not resting on their laurels. They're pushing into robotic-assisted surgery while keeping it familiar for surgeons used to manual instruments. Currently, SYK carries a Zacks Rank #3 (Hold), but the broader med-device space has some stronger performers. ISRG (Intuitive Surgical) is sitting at Rank #1 with a 15.7% estimated long-term earnings growth rate, and GEHC (GE HealthCare) is at Rank #2 with 9.1% growth. Worth keeping tabs on all three if you're building a healthcare portfolio. The T2 Alpha Humerus expansion is the kind of incremental but solid innovation that supports sustained revenue growth and deeper customer engagement. In a market hungry for solutions that improve both surgical outcomes and operational efficiency, this move positions Stryker well for the next cycle.
0
0
0
0